BCL6 and B-cell non-Hodgkin lymphoma: Evidence against FBXO11 as a redundant paralogue for BCL2 regulation comes from FBXO11 siRNA knockdown in human B cell lymphoma cells, which dramatically enhanced BCL6 protein stability after protein translation was pharmacologically blocked, but did not enhance BCL2 protein stability analysed in the same cell lysates [28].